A Taiwanese medical materials startup backed by the investment firm that bought Shohei Ohtani's 50th home run ball is going public on Taiwan's pre-listing market — a modest but real payday for early backers, with actual products still years away.

• Jelly Kang Biotech lists on Taiwan's emerging stock board at the end of August, after raising about NT$1 billion in a July funding round.
• Its big shareholder is Advantage Capital, the same firm that won the auction for Ohtani's 50-homer ball.
• The company makes dissolvable materials for breast reconstruction after cancer surgery, body filling, and cosmetic procedures.
• It is betting on the "body economy" created by GLP-1 weight-loss drugs, which leave patients wanting to restore lost volume.
• Revenue is far off: human trials on the breast product are not planned until early 2028, and its lifting-thread product is still awaiting Taiwanese approval.

Outlook: Expect the listing to trade on story rather than sales, with Japan market entry in 2027 the first real test of whether the technology sells.